company which mainly markets products for treatment in oncology . 1 clovis was founded in 2009 and is headquartered in boulder colorado . 2 the company is a publicly traded company on nasdaq under the symbol clvs 3 and is in the nasdaq biotechnology index 4 with several products in its product pipeline . 5 contents 1 pipeline 1.1 rociletinib 1.2 rucaparib 1.3 lucitanib 2 references 3 external links pipeline edit its products include rociletinib edit it has been suggested that this section be split out into another article titled rociletinib . discuss july 2016 it is developing rociletinib 6 which is in development as a treatment for non small cell lung cancer . 1 7 8 9 a phase iii trial has completed and in april 2016 an fda committee will consider recommending it for marketing approval . 10 if approved it would compete with astrazeneca s tagrisso osimertinib . 10 rucaparib edit rucaparib is a parp inhibitor in phase ii and iii clinical trials for advanced ovarian cancer . 11 lucitanib edit it has been suggested that this section be split out into another article titled lucitanib . discuss july 2016 lucitanib is a vegfr inhibitor . 12 it is also an inhibitor of fgfr1 and fgfr2 and has undergone clinical trials for advanced solid tumors . 13 including for metastatic breast cancer . 14 references edit a b clovis oncology a winning or losing lottery ticket . forbes . 2015 11 16 . retrieved 2016 01 04 . clvs profile . finance.yahoo.com . clovis oncology inc. . www.marketwatch.com . retrieved 4 january 2016 . overview nbi . nasdaq.com . retrieved 4 january 2016 . clovis oncology products & companion diagnostics . clovisoncology.com . 9 march 2015 . archived from the original on march 9 2015 . retrieved 4 january 2016 . williams sean 23 december 2015 . a festivus for the invest in us it s time for the airing of grievances . fox business . retrieved 4 january 2016 . wallace alicia . clovis oncology stock bludgeoned after delay in cancer drug approval . www.denverpost.com . retrieved 4 january 2016 . hclovis oncology announces regulatory update for rociletinib nda filing . www.reuters.com . retrieved 4 january 2016 . fda requests additional data for rociletinib in egfr t790m mutant nsclc . onclive . 2015 11 16 . retrieved 2016 01 04 . a b investors doubt efficacy of clovis lung cancer med rociletinib shares off 11 % . april 2016 rucaparib at clovis lucitanib at clovis soria ; et al. 2014 . phase i iia study evaluating the safety efficacy pharmacokinetics and pharmacodynamics of lucitanib in advanced solid tumors . . doi 10.1093 annonc mdu390 . cs1 maint explicit use of et al. link a phase ii trial testing oral administration of lucitanib in patients with fibroblast growth factor receptor fgfr 1 amplified or non amplified estrogen receptor positive metastatic breast cancer finesse external links edit clovis oncology retrieved from https en.wikipedia.org w index.php title clovis oncology & oldid 730534083 categories pharmaceutical companieshidden categories cs1 maint explicit use of et al.articles to be split from july 2016all articles to be split navigation menu personal tools not logged intalkcontributionscreate accountlog in namespaces article talk variants views read edit view history more search navigation main pagecontentsfeatured contentcurrent eventsrandom articledonate to wikipediawikipedia store interaction helpabout wikipediacommunity portalrecent changescontact page tools what links hererelated changesupload filespecial pagespermanent linkpage informationwikidata itemcite this page print export create a bookdownload as pdfprintable version languages add links this page was last modified on 19 july 2016 at 16 23 . text is available under the creative commons attribution sharealike license ; additional terms may apply . by using this site you agree to the terms of use and privacy policy . wikipedia is a registered trademark of the wikimedia foundation inc. a non profit organization . privacy policy about wikipedia disclaimers contact wikipedia developers cookie statement mobile view